tom1_tom1 Posted - 3 days ago

$XGN

Stock_Titan Posted - 04/30/24

$XGN Exagen to Announce First Quarter 2024 Results on May 13, 2024 https://www.stocktitan.net/news/XGN/exagen-to-announce-first-quarter-2024-results-on-may-13-7yaykqi1ei0k.html

Tshanky_ Posted - 04/23/24

$XGN 2H 2024

ChiefOG Posted - 04/17/24

$XGN 🌙

tom1_tom1 Posted - 04/09/24

$XGN

sylvp Posted - 03/19/24

$XGN when when when lol

DonCorleone77 Posted - 03/18/24

$XGN Exagen continues to execute on re-acceleration strategy, says Canaccord Canaccord reiterates a Buy rating and $5 price target on Exagen shares after the company announced Q4 results that were "well above" the firm's estimates and FactSet consensus and gave 2024 revenue guidance that was in line with FactSet consensus. The firm, which notes that Exagen's Q1 revenue guidance was above the firm's and the Street's estimate, says that it appears that Exagen's efforts to increase average selling price and reduce cash burn are paying dividends as the company continues to execute on its re-acceleration strategy.

Stocksrunner Posted - 03/18/24

🚀📈💥 MONDAY MARKET MOVERS! 💥📈🚀 🔥 Get ready for some adrenaline-pumping action as the market opens with these top gainers dominating the headlines! 🔥 1️⃣ $SMR Alphabet, Nvidia, PepsiCo, and more leading the charge higher! 🚀 Dow Jones up 100 points! 📈 Alphabet shares soaring 6.3% to $150.09! 📈 2️⃣ $ELTX making waves with a $6.0 million private placement financing announcement! 🌊💰 3️⃣ $CGC Marijuana stocks like Tilray and Canopy Growth rallying on DEA rescheduling chatter! 🌿📈 4️⃣ $SHCO Soho House skyrockets on reports of a takeover offer! 🏠🚀 5️⃣ $XGN reports strong Q4 results, exceeding revenue estimates! 💪💼

_StockTrader Posted - 03/18/24

Real-Time Stock Data $XGN Price: 1.89 Volume: 164501 Market Cap: 30852898 PE Ratio: -1.3507462 Powered by: OZSC

mikesterz7 Posted - 03/18/24

$XGN Financial Highlights: Record total revenue of $52.5 million for the full-year 2023, and total revenue of $13.8 million for the fourth quarter of 2023. Record 137,650 AVISE® CTD tests performed for the full-year 2023, including 30,438 tests for the fourth quarter of 2023. Over 900,000 AVISE® CTD tests performed to date since launch. AVISE® CTD trailing twelve-month average selling price (ASP) of $336, an increase of $51 over the course of the year. Delivered 56% gross margin for full-year 2023 and 59% for the fourth quarter of 2023. Net loss of $23.7 million for the full-year 2023 and $5.6 million for the fourth quarter of 2023. Adjusted EBITDA of $(17.1) million for the full-year 2023 and $(3.9) million in the fourth quarter of 2023. Cash balance of $36.5 million at year-end 2023.

DonCorleone77 Posted - 03/18/24

$XGN Exagen sees FY24 revenue $54M, consensus $54.13M For full-year 2024 revenue, the company is providing guidance of approximately $54 million. For first quarter 2024 revenue, the company is providing a guidance range of $13.0 million to $13.5 million. For full-year 2024, the company believes its adjusted EBITDA will be better than negative $20 million. Given the company's continued improved performance, we believe existing cash and cash equivalents are adequate to meet anticipated cash requirements into 2026.

DonCorleone77 Posted - 03/18/24

$XGN Exagen reports Q4 EPS (31c), consensus (43c) Reports Q4 revenue $13.8M, consensus $11.56M. "I am extremely proud of our team's commitment and hard work this past year. We transformed quite a bit at Exagen and together, we are steering the company towards profitability, with a sharp focus on increasing ASP while diligently driving down expenses and responsibly managing cash. The progress we've made in the past year has significantly bolstered the health of our organization. We look forward to serving our clinicians and patients in 2024 with a renewed organization which is very much focused on reaching our operating goals. Our strategy has been validated and I'm confident that the best is yet to come for Exagen," said John Aballi, President and Chief Executive Officer.

epsguid Posted - 03/18/24

$XGN reported a loss of $0.31, consensus was ($0.41) via @eWhispers #epsbeat http://eps.sh/d/xgn

Stock_Titan Posted - 03/18/24

$XGN Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results https://www.stocktitan.net/news/XGN/exagen-inc-reports-strong-fourth-quarter-and-full-year-2023-ywcu6ojm4gla.html

RealErnFranklin Posted - 03/10/24

$BREZ dont forget about brez 1.2mil float $XGN forum coming up. 1.80 safe cut spot. Looks good $BTM thinning out. 2.3’s bids look nice if filled $SVMH a real shot at going crazy with the new nikes and promos with em. Go nuts go $ hlbz scooter nuts. 🌰

Stock_Titan Posted - 03/08/24

$XGN Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum https://www.stocktitan.net/news/XGN/exagen-inc-to-participate-in-the-key-banc-capital-markets-life-wnnn0dd6wkby.html

Stock_Titan Posted - 03/07/24

$XGN Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024 https://www.stocktitan.net/news/XGN/exagen-to-announce-fourth-quarter-2023-and-full-year-financial-t5ro0ahqxrao.html

TickerDD_com Posted - 02/26/24

From 2/16/2024, looking back across 22 Month-Ends for XGN, Percentage Change of Average Monthly Price had More Negatives (55%) while Percentage Change of Average Monthly Volume had All Positives (100%) $XGN #XGN #XGNStock #TickerDD #XGNPrice https://www.youtube.com/watch?v=_xzAjzSBw00

UpsidePotential22 Posted - 02/20/24

$XGN Exagen: Enabling Timely Diagnosis for Lupus Patients Excited to share an article about Exagen Inc. (NASDAQ: XGN), a provider of autoimmune testing solutions. The Company's proprietary AVISE® CTD test may provide clinical utility and cater to the unmet needs of over 24 million patients in the United States suffering from diseases like SLE, RA, Sjögren’s syndrome, antiphospholipid syndrome (APS), other autoimmune-related diseases. Exagen's products have a total addressable market of approximately $7.5 billion. Over the last several years, there has been a growing adoption of AVISE® CTD, indicating that the market understands the value of Exagen's offerings - this makes the Company an interesting watch. Read on to know more: https://www.aviseanalytics.com/exagen-enabling-timely-diagnosis-for-lupus-patients/

Toyaga Posted - 02/08/24

$XGN Time to start loading up before Q4 and full FY updates. We know what we will see - higher revenue, deeper in the process for Avise Lupus LCD, development collaborations. The moment XGN adds another powerhouse test to complement Avise CTD, that stock will be going miles. Same G&A -> double revenue.

VrtcIl Posted - 01/29/24

Do not chase $XGN now, as doing so would require setting a stop-loss at a considerable distance from the entry point. Waiting for more favorable conditions can lead to a more manageable risk-reward ratio. Price: 2.33 Float: 8.7M Short Float: 0.1 % 💰 Dollar Volume: 3.6K ℹ️ USA | Diagnostics & Research

EarningsInsider Posted - 01/25/24

Exagen Sees Short Interest Decrease from 24,200 shares to 8,300 shares. $XGN https://www.marketbeat.com/stocks/NASDAQ/XGN/short-interest/

tickeron Posted - 01/23/24

Wow this is a big change! $XGN MACD Histogram turned negative on January 22, 2024. View odds of downtrend. https://srnk.us/go/4976980

cctranscripts Posted - 01/22/24

Sun Mountain Capital Partners, L.L.C. just provided an update on share ownership of Exagen Inc. https://www.conferencecalltranscripts.org/summary/?id=12884345 $XGN

tickeron Posted - 01/22/24

A.I.dvisor made a bullish call on $XGN, netting in a 12.25% gain over 5 days https://srnk.us/go/4976051

Louis_Profitlabfx Posted - 01/22/24

$AMD $NVDA Our FREE trial members saw a 46% profit on $SANA after our analyst's precise entry alert $XBP! $XGN Trial Link in Profile 👉 @Louis_Profitlabfx

tickeron Posted - 01/18/24

Good move or bad move? $XGN Aroon Indicator entered an Uptrend. View odds of downtrend. https://srnk.us/go/4972192

StockAutomatePro Posted - 01/18/24

$XGN The chart suggests a bullish outlook for the stock. We alerted the BUY signal at $2.14 and we were able to close this one with profit at $2.27 💯 See more details at StockAutomate.com

UltraAlgo Posted - 01/17/24

$XGN 16.01% down since our sell rating. See the AI powered signals in real-time at UltraAlgo.com

GraceAbounds Posted - 01/17/24

$XGN #tomorrow